Research programme: needle-free injectable therapeutics - Glide/Paladin

Drug Profile

Research programme: needle-free injectable therapeutics - Glide/Paladin

Latest Information Update: 16 May 2015

Price : $50

At a glance

  • Originator Glide Pharma
  • Developer Glide Technologies
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 23 Mar 2011 Needle-free injectable formulations of sumatriptan, octreotide and fentanyl have entered clinical development
  • 09 Aug 2007 Preclinical trials in Neuroendocrine tumours in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top